Table 2 Characteristics of subjects at baseline.
| Cohort 1* (n = 79) | Cohort 2† (n = 53) | Combined (n = 132) | |
|---|---|---|---|
| Female sex, n (%) | 63 (80) | 53 (100) | 116 (88) |
| Age, years | 60.7 (11)§ | 53.7 (5.3)§ | 57.9 (9.8) |
| African American race, n (%) | 12 (15) | 11 (21) | 23 (17) |
| BMI, kg/m2 | 30.2 (7.6)§ | 36.4 (6.3)§ | 32.7 (7.7) |
| Duration of symptoms, years | 5.4 (6.8) | 5 (6) | 5.2 (6.5) |
| Duration of self‐reported diagnosis, years | 2.4 (4)§ | 0.4 (0.9)§ | 1.6 (3.3) |
| Unilateral tibiofemoral OA, n (%) | 65 (82) | 36 (68) | 101 (77) |
| WOMAC knee pain score, range 5–25 | 8.8 (4.1) | 10.1 (4.2) | 9.3 (4.1) |
| WOMAC knee stiffness score, range 2–10 | 4 (2) | 4.5 (2) | 4.2 (2) |
| WOMAC function score, range 17–85 | 35.9 (13.8) | 37.7 (11.9) | 36.6 (13.1) |
BMI, body mass index; OA, osteoarthritis; WOMAC, Western Ontario and McMaster Universities.
*Community‐based longitudinal cohort.
†Subjects from the placebo group of a randomised controlled trial of doxycycline in knee OA.
‡The knee with grade 0–1 OA at baseline. If grade 0–1 changes were present bilaterally, the knee with the greater value (ie, longer duration or greater severity of pain/stiffness) was used.
§p<0.001 for comparison between cohorts.